OS
Fig. 2 · Panel Fig._2_OS_from_the_date_of_randomization_ITT_population_.
Panel Fig._2_OS_from_the_date_of_randomization_ITT_population_. 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Daisuke Kotani, Takayuki Yoshino, Toshiki Masuishi, Yu Sunakawa, Atsuo Takashima, Kentaro Yamazaki, Hisato Kawakami, Tomohiro Nishina, Yoshito Komatsu, Taito Esaki, Cathy Eng, Stacey Ukrainskyj, Rajash Pallai, Shivani Nanda, Zhao Yang, William Schelman, Marek Kania, Taroh Satoh
Int J Clin Oncol 30(10) 2043-2052
BACKGROUND: In the phase 3 FRESCO-2 study, fruquintinib plus best supportive care (BSC) significantly improved overall survival (OS) versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). We present the results of a FRESCO-2 post hoc subgroup analysis evaluating outcomes of patients enrolled in Japan. METHODS: In FRESCO-2, patients had previously received all standard chemotherapies, anti-VEGF and anti-EGFR therapies if indicated, and had progressed on, or were intolerant to trifluridine-tipiracil and/or regorafenib. Patients were randomized 2:1 to receive fruquintinib 5 mg or matching placebo by mouth once daily on days 1-21 in 28-day cycles, plus BSC. The primary endpoint was OS; secondary endpoints included progression-free survival (PFS) and safety. RESULTS: Of the 56 patients enrolled in Japan, 40 (71.4%) and 16 (28.6%) were randomized to fruquintinib and placebo, respectively. OS was improved with fruquintinib versus placebo (median 6.9 vs. 5.6 months; hazard ratio [HR], 0.42; 95% confidence interval [CI] 0.19 - 0.92). PFS was also improved with fruquintinib versus placebo (median 3.6 vs. 1.8 months; HR, 0.27; 95% CI 0.13 - 0.56). The incidence of grade ≥ 3 treatment-emergent adverse events (TEAEs) with fruquintinib versus placebo was 71.8% versus 29.4%; the most common grade ≥ 3 TEAEs with fruquintinib were hypertension (23.1%) and palmar-plantar erythrodysesthesia (17.9%). CONCLUSIONS: Fruquintinib improved OS and PFS versus placebo in FRESCO-2 patients enrolled in Japan and demonstrated a manageable safety profile. Results from the Japan subgroup were consistent with the global FRESCO-2 population, thus supporting fruquintinib as a novel treatment option for patients in Japan with refractory mCRC. CLINICAL TRIAL DETAILS: ClinicalTrials.gov; NCT04322539.
2 个 Figure · 2 个 KM 面板
Fig. 2 OS from the date of randomization (ITT population). BSC, best supportive care; CI, confidence interval; HR, hazard ratio; ITT, intention-to-treat; OS, overall survival
Fig. 2 · Panel Fig._2_OS_from_the_date_of_randomization_ITT_population_.
Panel Fig._2_OS_from_the_date_of_randomization_ITT_population_. 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 PFS from the date of randomization (ITT population). BSC, best supportive care; CI, confidence interval; HR, hazard ratio; ITT, intention-to-treat; PFS, progression-free survival
Fig. 3 · Panel Probability_of_PFS_vs._Time_since_date_of_randomization
Panel Probability_of_PFS_vs._Time_since_date_of_randomization 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。